169 related articles for article (PubMed ID: 37460393)
1. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract][Full Text] [Related]
2. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
4. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
Jayachandran G; Ueda K; Wang B; Roth JA; Ji L
PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer.
Zhang H; Shao F; Guo W; Gao Y; He J
Thorac Cancer; 2019 May; 10(5):1069-1077. PubMed ID: 30900384
[TBL] [Abstract][Full Text] [Related]
7. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
8. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
[TBL] [Abstract][Full Text] [Related]
10. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Mei Y; Liu YB; Hu DL; Zhou HH
Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
[TBL] [Abstract][Full Text] [Related]
11. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
14. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
15. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
17. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
18. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.
Xu Y; Tong Y; Zhu J; Lei Z; Wan L; Zhu X; Ye F; Xie L
BMC Cancer; 2017 May; 17(1):373. PubMed ID: 28545465
[TBL] [Abstract][Full Text] [Related]
19. Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.
Sun Y; Wang J; Ma Y; Li J; Sun X; Zhao X; Shi X; Hu Y; Qu F; Zhang X
J Exp Clin Cancer Res; 2021 Sep; 40(1):306. PubMed ID: 34587992
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
